Background The SELENA flare index (SFI) has functioned well in clinical and clinical trial settings (1), but has the limitation that it classifies only severe versus combined mild/moderate flares.

Objective We aimed to understand the role of the transcriptional co-factor Yes-associated protein (Yap) in the molecular pathway underpinning the pathogenic transformation of synovial fibroblasts (SF) ...

Correspondence to Dr Tristan Maerz, Department of Orthopaedic Surgery, University of Michigan, Ann Arbor, Michigan, USA; tmaerz{at}med.umich.edu Objectives Synovium is acutely affected following joint ...

Objectives Various hypotheses exist for the explanation of placebo response rates in randomised controlled trials (RCTs) of patients with rheumatoid arthritis with IR to methotrexate (MTX). We ...

Objective To examine the fracture risk with use of disease-modifying antirheumatic drugs (DMARDs), statins, proton pump inhibitors (PPIs), opioids, non-opioid analgesics and psychotropic medications ...

1 Department of Internal Medicine, Division of Rheumatology, University Hospital Maastricht, Maastricht, The Netherlands 2 Department of Rheumatology, Maasland Hospital Sittard, The Netherlands 3 ...

Objectives To evaluate the incidence of infection in patients with active rheumatoid arthritis (RA) treated with baricitinib, an oral selective Janus kinase (JAK)1 and JAK2 inhibitor. Methods ...

Background: Osteoarthritis (OA) is a degenerative disease of the joint occurring in elderly population. According to World Health Organization, its worldwide prevalence ranges from 11,8% to 12,7%.

Aims Treating to low disease activity is routine in rheumatoid arthritis, but no comparable goal has been defined for systemic lupus erythematosus (SLE). We sought to define and validate a Lupus Low ...

Objective To investigate the rate of serious bacterial, viral or opportunistic infection in patients with rheumatoid arthritis (RA) starting tocilizumab (TCZ) versus tumour necrosis factor inhibitors ...

Objectives To determine how gene expression profiles in osteoarthritis joint tissues relate to patient phenotypes and whether molecular subtypes can be reproducibly captured by a molecular ...

Objective Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a humanised type II ...